Join
Live feed
·
PRReleasevia Quantisnow
Nuvalent Inc. logo

Nuvalent Announces Timing of Pivotal Data for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC from ARROS-1 Clinical Trial of Zidesamtinib

ByQuantisnow·Wall Street's wire, on your screen.
NUVL· Nuvalent Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NUVL (Nuvalent Inc.) and more on Quantisnow.